Purpose
The three components of this stack cover three commonly discussed molecular axes of biological ageing research: telomere biology, mitochondrial/AMPK signalling, and NAD+/sirtuin availability. None of them is a treatment for ageing; each is a research reagent whose administration protocols come from animal-model and preliminary human work.
Component peptides
- Epithalon — 5–10 mg daily during a 10-day course; the pineal-tetrapeptide component with reported telomerase-related effects in cell-culture and rodent-longevity studies.
- MOTS-c — 5–10 mg subcutaneously, two or three times weekly; the mitochondrial-derived-peptide component characterised in AMPK-activation and exercise-adaptation research.
- NAD+ — 50–100 mg subcutaneously, two or three times weekly; the redox/sirtuin cofactor component.
Timing & rotation
Research writeups typically describe the following pattern:
- Weeks 1–2 (days 1–10): Epithalon 5–10 mg daily, subcutaneous. NAD+ and MOTS-c begin in parallel on day 1.
- Weeks 3–4: MOTS-c and NAD+ continue at their reported frequencies; Epithalon is complete.
- Weeks 5–24: Washout.
- Repeat the cycle twice per year.
The cycling rationale in the literature is to concentrate the Epithalon exposure into a short pulse (matching the animal-study protocols) and to keep total systemic exposure to MOTS-c and NAD+ bounded.
Reconstitution & math
- Epithalon 10 mg vial in 2 mL BAC → 5,000 mcg/mL; 5 mg dose = 1.0 mL = 100 units.
- MOTS-c 10 mg vial in 2 mL BAC → 5,000 mcg/mL; 5 mg dose = 1.0 mL = 100 units.
- NAD+ 500 mg vial in 5 mL BAC → 100 mg/mL; 100 mg dose = 1.0 mL = 100 units.
Use the calculators on each component page to model alternative vial sizes.
Reported outcomes
Rodent longevity studies report increases in mean lifespan and delayed onset of age-related decline in various parameters with individual components; human-outcome data on the combination remain preliminary. No randomised human trial has evaluated the stack.
References
See the individual profiles for Epithalon, MOTS-c, and NAD+.